A cute esophageal variceal bleeding (EVB) remains among the most serious emergencies managed by gastroenterologists and hepatologists. Most patients do well during the acute episode with current endoscopic and pharmacologic therapy. In this issue of HEPATOLOGY, Escorsell and colleagues report a randomized trial comparing a very old and a very new intervention for the challenging minority of patients with refractory acute EVB.(1)
Acute EVBCurrent guidelines recommend endoscopic ligation and vasoactive medication for treatment of acute EVB, with consideration of transjugular intrahepatic portosystemic shunt in high-risk patients.(2) Randomized trials indicate that 2%-13% of patients with acute EVB treated as recommended have persistent or recurrent bleeding over 5 days or during hospitalization. (3,4) Consensus guidelines recommend transjugular intrahepatic portosystemic shunt for patients who have persistent bleeding despite initial endoscopic and medical therapy, while a second endoscopic treatment may be tried if bleeding recurs after initial hemostasis. (2) Balloon tamponade is currently recommended only for refractory EVB as a temporary bridge to definitive therapy.(2) However, randomized trials have not focused solely on patients with persistent active bleeding despite endoscopic and medical intervention, the high-risk group in whom balloon tamponade may be considered.
Balloon TamponadeBalloon tamponade is among the oldest therapies used for variceal bleeding. Case series suggest initial bleeding control in 90% of patients.(5) Major complications, including esophageal rupture, airway obstruction, and aspiration pneumonia, occur in 12% of patients and may be lethal.(5) Deaths attributed to use of balloon tamponade occurred in 6% of patients in these series. (5) Randomized trials comparing tamponade to medical therapy with vasopressin, somatostatin, or terlipressin reveal no significant difference in initial control of bleeding or mortality. Randomized trials comparing tamponade to sclerotherapy for EVB show trends or significant benefit for sclerotherapy in initial hemostasis, and all indicate better sustained or definitive hemostasis with sclerotherapy. (6)(7)(8) Thus, tamponade for acute EVB is not better than medical therapy, is less effective than endoscopic therapy, and not uncommonly causes serious and sometimes fatal complications. My view has been that the use of tamponade should be exceedingly rare: e.g., patients with persistent massive known EVB awaiting endoscopy or awaiting transjugular intrahepatic portosystemic shunt after unsuccessful endoscopic intervention.
Self-Expanding Metal StentsThe removable covered self-expanding metal stent used by Escorsell et al. was designed specifically to treat EVB Abbreviation: EVB, esophageal variceal bleeding.